Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAS-nomacopan
- Development stage
- Preclinical
- Lead developer
- Akari Therapeutics
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravitreal, Ophthalmic
01
Overview
PAS-nomacopan is a long-acting recombinant protein therapeutic designed as a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), developed for intravitreal injection in the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration. The drug leverages PASylation technology to extend its half-life in the eye, potentially allowing for dosing intervals of three months or longer—meaning only three or four injections per year may be needed. By inhibiting both complement C5 and LTB4 pathways, PAS-nomacopan aims to slow GA lesion progression while reducing the risk of choroidal neovascularization (CNV), a complication associated with current complement-only inhibitors. The drug is being developed by Akari Therapeutics and has completed preclinical development with plans for an IND submission in 2025[1][2][3][5][6].
- Other names
- nomacopancoversinEV 576EV576EV-576rEV 576rEV576rEV-576rVA576rVA-576rVA 576
02
Targets
C5
Beyond the preview
Go deeper on PAS-nomacopan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAS-nomacopan.